-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Of6hn8ekcb4DjYdv1gA9+/e8un5W8gE9UPFKHEGvosiHvz6WseJAXLZ/g4TfRDPr fbZUV3Uzt68L09pBSieT3g== 0001201617-04-000001.txt : 20040817 0001201617-04-000001.hdr.sgml : 20040817 20040817161953 ACCESSION NUMBER: 0001201617-04-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040813 FILED AS OF DATE: 20040817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PERLMAN ANDREW J CENTRAL INDEX KEY: 0001201617 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 333-89177 FILM NUMBER: 04982228 BUSINESS ADDRESS: STREET 1: TULARIK INC STREET 2: 1120 VETERANS BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TULARIK INC CENTRAL INDEX KEY: 0000889057 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943148800 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1120 VETERANS BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508257300 MAIL ADDRESS: STREET 1: 1120 VETERANS BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgar.xml PRIMARY DOCUMENT X0202 4 2004-08-13 1 0000889057 TULARIK INC TLRK 0001201617 PERLMAN ANDREW J C/O TULARIK INC. 1120 VETERANS BLVD. SO. SAN FRANCISCO CA 94080 0 1 0 0 Executive Vice President Common Stock 2004-08-13 4 D 0 24850 D 0 D Common Stock 2004-08-13 4 D 0 943.15 D 0 I By 401(k) Trust Common Stock 2004-08-13 4 D 0 327386 D 0 I By Family Trust Common Stock 2004-08-13 4 D 0 42000 D 0 I By Trust Stock Option (right to buy) 3.00 2004-08-13 4 D 0 13333 D 2007-06-08 Common Stock 13333 0 D Stock Option (right to buy) 3.00 2004-08-13 4 D 0 50000 D 2008-06-17 Common Stock 50000 0 D Stock Option (right to buy) 3.00 2004-08-13 4 D 0 30000 D 2009-06-17 Common Stock 30000 0 D Stock Option (right to buy) 3.00 2004-08-13 4 D 0 20000 D 2009-11-05 Common Stock 20000 0 D Stock Option (right to buy) 23.125 2004-08-13 4 D 0 59955 D 2010-06-07 Common Stock 59955 0 D Stock Option (right to buy) 22.25 2004-08-13 4 D 0 4494 D 2011-04-19 Common Stock 4494 0 D Stock Option (right to buy) 22.25 2004-08-13 4 D 0 35506 D 2011-04-19 Common Stock 35506 0 D Stock Option (right to buy) 8.73 2004-08-13 4 D 0 44779 D 2012-11-19 Common Stock 44779 0 D Stock Option (right to buy) 8.73 2004-08-13 4 D 0 5221 D 2012-11-19 Common Stock 5221 0 D Stock Option (right to buy) 4.88 2004-08-13 4 D 0 125000 D 2013-03-20 Common Stock 125000 0 D Total of non-derivative securities directly owned included 430 shares, 5,165 shares and 530 shares Tularik common stock acquired under Tularik's Employee Stock Purchase Plan on July 31, 2003, January 30, 2004 and July 30, 2004, respectively. Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 11,207 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement. Total of non-derivative securities indirectly owned under the 401(k) Trust included 297.03 shares and 61.10 shares Tularik common stock acquired on March 31, 2003 and March 31, 2004, respectively. Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 425 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement. Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 147,651 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement. The reporting person disclaims beneficial ownership of such securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16, or for any other purpose. Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 18,942 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement. This option, which was fully vested on June 9, 2001, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 6,013 shares of Amgen common stock for $6.66 per share. This option, which was fully vested on March 17, 2003, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 22,549 shares of Amgen common stock for $6.66 per share. This option, which was fully vested on March 17, 2004, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 13,530 shares of Amgen common stock for $6.66 per share. This option, which was fully vested on August 5, 2004, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 9,020 shares of Amgen common stock for $6.66 per share. This option, which was vested as to 45,379 Tularik common shares as of the date of this filing and provided for the remaining 14,576 shares to vest in equal monthly installments until full vest on March 7, 2005, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 27,038 shares of Amgen common stock for $51.28 per share. This option, which was vested as to 3,093 Tularik common shares as of the date of this filing and provided for the remaining 1,401 shares to vest in equal monthly installments until full vest on November 20, 2005, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 2,026 shares of Amgen common stock for $49.34 per share. This option, which was vested as to 22,139 Tularik common shares as of the date of this filing and provided for the remaining 13,367 shares to vest in equal monthly installments until full vest on February 20, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 16,013 shares of Amgen common stock for $49.34 per share. This option, which was vested as to 18,136 Tularik common shares as of the date of this filing and provided for the remaining 26,643 shares to vest in equal monthly installments until full vest on October 28, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 20,195 shares of Amgen common stock for $19.36 per share. This option, which was vested as to 3,739 Tularik common shares as of the date of this filing and provided for the remaining 1,482 shares to vest in equal monthly installments until full vest on December 28, 2005, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 2,354 shares of Amgen common stock for $19.36 per share. This option, which provided for monthly vesting beginning April 21, 2003 until full vest on March 21, 2007, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 56,374 shares of Amgen common stock for $10.83 per share. Valerie L. Pierce, as Attorney in Fact for Andrew J. Perlman 2004-08-16 -----END PRIVACY-ENHANCED MESSAGE-----